Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci Buys 49,261 Shares of Stock

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci purchased 49,261 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was acquired at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the acquisition, the chief executive officer now directly owns 1,097,458 shares of the company’s stock, valued at $1,108,432.58. This represents a 4.70 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Acurx Pharmaceuticals Stock Performance

ACXP traded down $0.06 during trading on Wednesday, reaching $0.75. The company’s stock had a trading volume of 1,695,648 shares, compared to its average volume of 877,882. The company’s fifty day moving average price is $1.21 and its 200-day moving average price is $1.79. The company has a market capitalization of $12.69 million, a price-to-earnings ratio of -0.69 and a beta of -1.71. Acurx Pharmaceuticals, Inc. has a 52-week low of $0.68 and a 52-week high of $5.28.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter last year, the firm earned ($0.24) EPS. Equities analysts predict that Acurx Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC raised its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 6.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 295,075 shares of the company’s stock after purchasing an additional 16,975 shares during the period. Prospect Financial Services LLC owned about 1.86% of Acurx Pharmaceuticals worth $561,000 at the end of the most recent reporting period. Institutional investors own 11.53% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Acurx Pharmaceuticals in a report on Tuesday, December 10th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.